EU Finalizes Agreement for Extra 300M Pfizer COVID-19 Vaccines

Date: February 10, 2021 | Country: BELGIUM | Region: EUROPE | Type: Pricing & Reimbursement | Keywords: #comirnaty #covid-19 #ema #initiative #janssen #johnson #pre #purchase

PRICENTRIC BRIEF:

  • The European Commission has purchased 300 million additional doses of the Pfizer/BioNTech COVID-19 vaccine, dubbed “Comirnaty”
  • The news comes as the Pfizer jab has been found to be effective against new variants of the virus detected in both South Africa and the United Kingdom
  • As it stands, the Commission now has contracts with AstraZeneca (400 million doses), Sanofi-GSK (300 million doses), Johnson and Johnson (400 million doses), BioNTech-Pfizer (600 million doses), CureVac (405 million doses) and Moderna (160 million doses)

 

THE DETAILS

BRUSSELS, Belgium – The European Commission has finalized an agreement for 300 million additional doses of the Pfizer/BioNTech COVID-19 vaccine, dubbed “Comirnaty”.

An initial supply agreement was reached in November 2020 but has now been finalized by the Commission and Pfizer. It brings the Commission’s overall order to 600 million doses.

The news comes as the Pfizer jab has been found to be effective against new variants of the virus detected in both South Africa and the United Kingdom.

The European Medicines Agency (EMA) also recently released a safety update on the Pfizer vaccine, confirming the vaccine’s safety profile following data collection and notes that no new side effects were discovered.

As it stands, the Commission now has contracts with AstraZeneca (400 million doses), Sanofi-GSK (300 million doses), Johnson and Johnson (400 million doses), BioNTech-Pfizer (600 million doses), CureVac (405 million doses) and Moderna (160 million doses).

OPEN Initiative 

The European Medicines Agency (EMA) recently unveiled a new initiative focused on increasing collaboration between European Union (EU) and non-EU drug regulators, ultimately allowing for faster and easier evaluation of COVID-19 vaccines.

The project, dubbed “OPEN”, actually started in December 2020, but has only just been made public knowledge. The EMA launched it in the hopes that it will foster a better understanding of regulatory outcomes while retaining scientific and regulatory independence of the participating authorities.

Australia, Canada, Japan, Switzerland and the World Health Organization (WHO) have been named as the primary participators, under the terms of existing confidentiality arrangements.

Learn more about Pricentric ONE and our Global Pricing Solutions!

Contact us with your questions and global pricing needs, and an expert will follow up shortly.